BioSpace News Archive

A first-of-its-kind study published in AACC’s Clinical Chemistry journal shows that a novel drug test detects a new class of synthetic cannabinoids called OXIZIDs.

Sensei Biotherapeutics, Inc. presented additional preclinical data on SNS-101, a monoclonal antibody targeting the immune checkpoint VISTA, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival.

Nanoscope Therapeutics Inc. announced that management will present at Chardan’s 6th Annual Genetic Medicines Conference on Monday, October 3, 2022, in New York.

Clene Inc. along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, announced that it will report topline results of the CNM-Au8® regimen of the HEALEY ALS Platform Trial on Monday, Oct. 3.

Adverum Biotechnologies, Inc. announced new analyses from the OPTIC study treating wet age-related macular degeneration during the Late Breaking Developments portion of Retinal Subspecialty Day at the American Academy of Ophthalmology 2022 Annual Meeting in Chicago, Illinois.

Stealth BioTherapeutics Corp announced that Robert Weiskopf, Stealth’s chief financial officer, is leaving the company effective September 30, 2022.

In an important proof-of-concept study in the field of xenotransplantation, experts at Cincinnati Children’s have demonstrated that embryos from interspecies chimeras can be used as bioreactors to produce bone marrow cells needed for transplant procedures to treat leukemias and other blood disorders.

Adicet Bio, Inc. announced it granted inducement awards on September 30, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to four individuals hired by Adicet in September 2022.